Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of Matter patent protection in the UK, moves towards Phase I clinical trial in H2 2022 on positive preclinical data LONDON, March 10, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF)…


Previous articleNuminus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
Next articleAlbert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange